Celgene's Long-Lasting Underperformance
If an average Joe invested $100 in Celgene's (NASDAQ:CELG) stock in 2015, he would have lost $17 now. At the same time, if he invested in the S&P 500 (SPY) or the Nasdaq Biotech ETF (IBB), he would have gained $30 and $2 respectively.
CELG data by YChartsCelgene clearly underperformed and missed investors' expectations in the last three years. It has been and continues to be a Revlimid company that has not been yet able to substantially diversify its sales and define its future after Revlimid.
